Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

Phase 1 Terminated 15 enrolled Bayer

Non-randomizedSequentialOpen-labelTreatment

Summary

Determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), and/or recommended Phase II dose (RP2D) of oral BAY 1143269 given alone or in combination with intravenous (IV) docetaxel in subjects with advanced solid tumors.

Timeline

Start: 2015-06-15
Primary completion: 2017-03-27
Completion: 2017-04-24

Outcome

Outcome not reported

Stopped: “Study stopped due to project prioritization”

Publications

Luo H, Huang S. Inhibition of MNK pathway sensitizes nasopharyngeal carcinoma to radiotherapy. Anticancer Drugs. 2024 Feb 1;35(2):155-162. doi: 10.1097/CAD.0000000000001542. Epub 2023 Sep 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BAY1143269	Unknown	5 mg	Oral
Subject	BAY1143269	Unknown	10 mg	Oral
Subject	BAY1143269	Unknown	25 mg	Oral
Subject	BAY1143269	Unknown	50 mg	Oral

Indications

No indication recorded.